WHO welcomes new evidence on the use of antiretrovirals

Man holding HIV medicines, Indonesia
WHO/Gary Hampton

26 February 2015 – WHO welcomes results presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) 2015 on using antiretrovirals (ARVs) in pre-exposure prophylaxis (PrEP) and treatment of HIV infection. Results from the TEMPRANO trial, conducted in Western Africa, have confirmed – for the first time in a randomized controlled trial – the individual health benefits for people who start antiretroviral therapy (ART) immediately after diagnosis.

“Smart” syringes to help prevent spread of HIV, hepatitis

24 February 2015 – WHO has launched a new policy on injection safety, which recommends the use of “smart” syringes that cannot be used more than once. “Adoption of safety-engineered syringes is absolutely critical to protecting people worldwide from becoming infected with HIV, hepatitis and other diseases. This should be an urgent priority for all countries,” says Dr Gottfried Hirnschall, Director of the WHO HIV/AIDS Department. The policy also aims to better control the spread of infections and to reduce the number of unnecessary injections that are leading to more infections.

HIV/TB researchers call for increased use of isoniazid preventive therapy

A health worker holds up an X-ray in a consulting room

24 February 2015 – HIV/TB researchers have called for progress in isoniazid preventive therapy at the ninth meeting on HIV/TB research, organized by WHO in conjunction with the annual Conference on Retroviruses and Opportunistic Infections (CROI), in Seattle, USA, on 23 February 2015. The meeting opened with remarks by United Nations Special Envoy on Tuberculosis Eric Goosby, who briefly shared plans to support the advancement of TB research, now included as one of the three pillars of the WHO’s new End TB Strategy.

Strategic and Technical Advisory Committee for hepatitis

22 February 2015 – The second meeting of WHO’s Strategic and Technical Advisory Committee for viral hepatitis (STAC-HEP) reviewed the implementation of recommendations made at the first STAC-HEP meeting, and discussed the development of the first global health strategy on viral hepatitis for 2016–2021. The meeting, which took place in Geneva, Switzerland, on 19–20 February 2015, also discussed the development of key WHO normative guidelines to support national responses to viral hepatitis epidemics.

Top stories

fact buffet

11.7 million At the end of 2013, 11.7 million people had access to antiretroviral therapy in low- and middle-income countries.

Fact sheet on HIV/AIDS

35 millionAt the end of 2013, 35 million people were living with HIV.

Online Q&A about HIV/AIDS

28 million Over 28 million people are eligible for antiretroviral therapy, under WHO 2013 consolidated ARV guidelines.

10 facts on HIV

Global Health Sector Strategy on HIV/AIDS 2011-2015: Let’s do what’s right for everyone

Global Hepatitis Programme

Contact us

World Health Organization
HIV/AIDS Department
20, Avenue Appia
CH-1211 Geneva 27